Skandinaviska Enskilda Banken AB publ reduced its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 41.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 467,323 shares of the biotechnology company’s stock after selling 328,803 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in United Therapeutics were worth $59,761,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Regal Investment Advisors LLC lifted its position in shares of United Therapeutics by 17.4% during the 3rd quarter. Regal Investment Advisors LLC now owns 17,554 shares of the biotechnology company’s stock worth $2,245,000 after buying an additional 2,596 shares during the last quarter. WINTON GROUP Ltd lifted its position in shares of United Therapeutics by 175.9% during the 3rd quarter. WINTON GROUP Ltd now owns 92,259 shares of the biotechnology company’s stock worth $11,798,000 after buying an additional 58,814 shares during the last quarter. Unison Advisors LLC purchased a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $224,000. HL Financial Services LLC lifted its position in shares of United Therapeutics by 22.6% during the 3rd quarter. HL Financial Services LLC now owns 3,324 shares of the biotechnology company’s stock worth $425,000 after buying an additional 613 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $2,816,000. 95.71% of the stock is currently owned by hedge funds and other institutional investors.
UTHR stock opened at $117.56 on Thursday. United Therapeutics Co. has a 12 month low of $100.57 and a 12 month high of $152.55. The firm has a market capitalization of $5.10 billion, a P/E ratio of 10.80, a price-to-earnings-growth ratio of 27.09 and a beta of 1.23. The company has a quick ratio of 4.05, a current ratio of 4.32 and a debt-to-equity ratio of 0.09.
Several analysts have recently weighed in on UTHR shares. TheStreet upgraded shares of United Therapeutics from a “c+” rating to a “b” rating in a research report on Thursday, August 16th. BidaskClub upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, July 11th. Wedbush set a $253.00 price objective on shares of United Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, October 12th. Finally, HC Wainwright set a $95.00 price target on shares of United Therapeutics and gave the company a “hold” rating in a research report on Monday, August 13th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $136.25.
In other United Therapeutics news, Director Christopher Causey sold 810 shares of the business’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $118.00, for a total value of $95,580.00. Following the transaction, the director now directly owns 3,925 shares of the company’s stock, valued at approximately $463,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard Giltner sold 3,240 shares of the business’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total transaction of $419,191.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,860 shares of company stock valued at $611,161. 8.20% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This story was posted by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.wkrb13.com/2018/11/09/skandinaviska-enskilda-banken-ab-publ-decreases-stake-in-united-therapeutics-co-uthr.html.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More: Conference Calls and Individual Investors
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.